Navigation Links
MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:3/11/2008

Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX releases CEO message #22
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
4. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
5. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
8. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. NeoStem to Present at Third Annual Stem Cell Summit in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... 2014 Dr. Carl Peck, ... today that Janet B. Arrowsmith, MD, has joined ... Partners Premier Experts are top tier consultants whose ... extraordinary value to the company’s clients. Premier Experts ... help clients successfully develop their medical products, pursue ...
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Today the Academy ... the United States Court of Appeals for the D.C. Circuit ... Aircraft published in the Federal Register on June 25, 2014. ... is contrary to the text and intent of the FAA ... violates Congress’ specific prohibition on any new rules or regulations ...
(Date:8/22/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... Biorem,s complete 2014 second quarter financial statements and MD&A have been filed ... June 30, , Six-months ended June 30, ( in CDN$,000 ... , 2014 , 2013 Revenue , 2,459 ... Gross profit , 56 , 1,485 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... IgG1 Using UNOsphere S and CHT , ... , Henry Lai, PhD, and Samuel G Franklin, PhD, ... USA , , ... a variety of sources have been purified , using ...
... Agencourt offers primer walking sequencing of PCR products, ... submit your template in either raw or , ... Select from either single stranded coverage for confirmation sequencing , ... clone validation , purposes. , ...
... , RNAClean is a ... isolates RNA or cDNA from in vitro transcription, cDNA or RNA ... As gene expression profiling , analysis and ... effective, automated purification reagent is required. Traditional purification , ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4Primer Walking 2RNA & cDNA Purification Using RNAClean 2RNA & cDNA Purification Using RNAClean 3RNA & cDNA Purification Using RNAClean 4RNA & cDNA Purification Using RNAClean 5
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the ... North America 2014-2018"  report to their ... , , ,Biometrics is a technology ... individuals based on their physical or ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information for ... University of California, Riverside in its 2014 list of ... times." , To generate the list, the company analyzed ... whose published work has had enormous impact. , The ... individuals who published the greatest number of highly cited ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... infants should focus not only on what babies are being ... to a study to be presented Saturday, April 28, at ... Adding cereal to bottles is one unhealthy practice that is ... lead to overfeeding and excess weight gain in infants. ...
... change can greatly impact biological species and ecosystems, ... to accommodate habitat shifts. Recorded data already ... to regions where their climatic requirements are better ... and regulators on climate change implications for local ...
... beauty as a tourist draw can boost conservation in ... ticket out of poverty for the humans who live ... who benefit most from nature-based tourism are people who ... time breaking into the tourism business, according to the ...
Cached Biology News:Low-income moms under stress may overfeed infants 2Workshop to focus on conservation management and climate change 2Can nature's beauty lift citizens from poverty? 2Can nature's beauty lift citizens from poverty? 3
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Pronase Reagent...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: